Truist initiated coverage of Immunovant (IMVT) with a Hold rating and $16 price target IMVT1402 appears to drive deeper IgG reductions than other FcRn inhibitors, but the firm thinks 1402 is too far behind in certain indications to gain meaningful traction in the market, the analyst tells investors. While aligned with the strategy of pursuing indications where 1402 would be first in class, the firm also notes that “meaningful de-risking” for these is not expected until 2027.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Immunovant price target lowered to $33 from $37 at JPMorgan
- 3 Best Stocks to Buy Now, 9/4/2025, According to Top Analysts
- Immunovant’s Batoclimab Shows Promising Results in Phase 2 Study for Graves’ Disease, Earning Buy Rating
- Immunovant’s Promising Clinical Data and Strategic Advancements Drive Buy Rating
- Immunovant Announces Promising Graves’ Disease Study Results